All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Mosunetuzumab receives European Commission approval for the treatment of relapsed or refractory follicular lymphoma
On June 8, 2022, it was announced that the European Commission (EC) has granted approval for the use of mosunetuzumab, a CD20 × CD3 T-cell engaging bispecific antibody, for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received ≥2 lines of systemic therapy. The approval is based on data obtained from the phase I/II GO29781 trial (NCT02500407),1 previously reported on the Lymphoma Hub.
Efficacy1
- 80% overall response rate
- 60% complete response rate
- Median duration of response was 22.8 months
Safety1
- Overall, 39% of patients experienced any-grade cytokine release syndrome, with 14% being Grade 2.
- Most common adverse events were neutropenia, pyrexia, hypophosphatemia, and headache.
- Initial treatment dose was administered without mandatory hospitalization.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?
